×
About 118,953 results

The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons
https://clinicaltrials.gov/ct2/show/NCT03538665

May 20th, 2022 - BACKGROUND: Endometrial cancer is the most common and second deadliest gynecological cancer in women in the United States, with over 63,000 new cases and 11,000 deaths expected to occur in 2018. Unlike most cancers, endometrial cancer incidence and mortality are increasing, due to increases in risk factors such as obesity and population aging. Racial disparities in endometrial cancer incidence ...

Emphysema Research Registry and Biosample Repository
https://clinicaltrials.gov/ct2/show/NCT00307281

May 20th, 2022 - The Emphysema/COPD Research Center will enroll up to 3000 subjects at the University of Pittsburgh. The experimental procedures that will be conducted as a part of the Emphysema Research Registry include gathering basic personal information (e.g., name, address, phone number, etc.), asking basic screening questions (which may involve the examination of past, current, and future medical records ...

A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT03549104

May 20th, 2022 - In persons with type 1 diabetes (T1DM), hypoglycemia is the major limiting factor in achieving optimal blood glycemic control. All persons with T1DM are at risk for hypoglycemia (blood glucose level < 70 mg/dl), which is life-threatening and accompanied by serious physical and psychological symptoms, resulting in a profound fear of hypoglycemia (FOH) and reduced quality of life. Young adults wi...

Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging
https://clinicaltrials.gov/ct2/show/NCT03478917

May 20th, 2022 - Painful vasoocclusive crisis (VOC) is the most frequent acute clinical manifestation of sickle cell disease (SCD), frequently necessitating emergency department visits and/or hospitalization. Approximately 10-30% of patients admitted to the hospital with a VOC will go on to develop acute chest syndrome (ACS), a complication of SCD resulting in significant morbidity and mortality. While ACS rela...

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT01867333

May 20th, 2022 - Background: Enzalutamide is a well-tolerated, modern androgen receptor antagonist (ARA) with more enhanced anti-tumor activity compared to previous ARAs. Phase III trial has demonstrated a 4.8 month improvement in survival and a 37% risk reduction in death in metastatic castration resistant prostate cancer (mCRPC) patients who have had previous docetaxel. PROSTVAC is a therapeutic cancer vaccin...

Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
https://clinicaltrials.gov/ct2/show/NCT02089789

May 20th, 2022 - Congenital disorders of glycosylation (CDGs) are a group of diseases characterized by an abnormal glycosylation of proteins, but that can also result from an abnormal synthesis of glycosaminoglycans, glycophospholipids or glycosylphosphatidylinositol or the abnormal synthesis or utilization of dolichols. CDGs were first described in 1980, but the initial description of mutations in a gene under...

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
https://clinicaltrials.gov/ct2/show/NCT04754802

May 20th, 2022 - This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during an induced public speaking challenge. Subject participation in the Study will last a total of 3 to 7 weeks, depending on the duration of the screening period and interv...

A Natural History Study of Children and Adults With Olfactory Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT04755205

May 20th, 2022 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 cases per year in the United States). ONB most frequently arises in adults aged 20-60 years. Pediatric ONB is particularly rare, with only small case ...

Developing Brain, Impulsivity and Compulsivity
https://clinicaltrials.gov/ct2/show/NCT04631042

May 20th, 2022 - Study Description: Many neuropsychiatric disorders have extreme impairing impulsivity and compulsivity behaviors at their core. We hypothesized that the development of symptoms of impulsivity and compulsivity during childhood/adolescence and early adulthood will be associated with atypical trajectories of brain features including cortical glutamate (the main excitatory neurotransmitter) and fun...

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
https://clinicaltrials.gov/ct2/show/NCT04645147

May 20th, 2022 - Study Description: Phase 1 study to evaluate the safety and immunogenicity of a 3-dose vaccination regimen of an adjuvanted EBV gp350-Ferritin nanoparticle vaccine. Based on data reported in animal studies, our hypothesis is that this EBV vaccine will be safe and will induce a potent EBVgp350-specific immune response. Twenty EBV seropositive participants and 20 EBV seronegative participants wil...

Cost-effectiveness of ICE With MOWOOT
https://clinicaltrials.gov/ct2/show/NCT04666155

May 20th, 2022 - The study will assess clinical effectiveness by means of quantitative and qualitative variables, and the cost effectiveness by means of economic outcomes.

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
https://clinicaltrials.gov/ct2/show/NCT00942981

May 20th, 2022 - OBJECTIVES Dopaminergic (DA) modulation of brain function is disturbed in several disabling psychiatric disorders and represents the target of key psychopharmacologic agents, such as neuroleptics. Schizophrenia has been considered a prototype of dysregulated DA signaling, with associated prefrontal cortex (PFC) dysfunction. Prevailing views attribute key symptoms of schizophrenia to deficient D...

Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension
https://clinicaltrials.gov/ct2/show/NCT04715113

May 20th, 2022 - To study the effect of acute normobaric hypoxia during exercise in patients with pulmonary hypertension on blood markers (serum markers of iron and red blood cell homeostasis and micro-RNAs known to be associated with PH).

A Longitudinal Study of COVID-19 Sequelae and Immunity
https://clinicaltrials.gov/ct2/show/NCT04411147

May 20th, 2022 - Title: A Longitudinal Study of COVID-19 Sequelae and Immunity Study Description: This is a longitudinal cohort study to evaluate the clinical sequelae of acute COVID-19 and characterize the immune response to SARS-CoV-2. Household contacts of the COVID-19 cohort will also be recruited and serve as a control group. Objectives: Characterize the medical sequalae and persistent symptoms following r...

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
https://clinicaltrials.gov/ct2/show/NCT04435600

May 20th, 2022 - Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms....

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
https://clinicaltrials.gov/ct2/show/NCT00271622

May 20th, 2022 - The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders. The evaluations will help determine if the participant meets criteria for participation in research protocols of the Pediatric and Developmental Neuroscience Branch (PDN) at the National Institute...

Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
https://clinicaltrials.gov/ct2/show/NCT04408950

May 20th, 2022 - Immunological disorders predispose affected individuals to a myriad of complications, including infection, immune dysregulation with autoimmune disease and aberrant inflammatory responses, and malignancy. Advances in genetic testing have propelled the discovery of the genetic underpinnings of numerous immunodeficiencies. However, a more complete picture of the immune system is needed to better ...

Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic
https://clinicaltrials.gov/ct2/show/NCT04419870

May 20th, 2022 - Infection is a major cause of morbidity and mortality individuals with mitochondrial disease, frequently triggering metabolic decompensation, multiorgan dysfunction, and neurologic deterioration. In the context of the recent COVID19 pandemic, people with mitochondrial disease are at increased risk for severe disease and poor outcomes if infected. However, the mechanisms for this link between in...

Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients
https://clinicaltrials.gov/ct2/show/NCT04669574

May 20th, 2022 - Background: Sleep disturbances are among the most common and severe symptoms reported in the Primary Brain Tumor (PBT)population and incidence rates are associated with oncologic therapies, particularly radiotherapy. Smart wearable devices have the potential to provide detailed information about sleep and circadian rhythms in human subjects with lower potential for data loss, as devices sync au...

Acetazolamide Efficacy in Ataxia in PMM2-CDG
https://clinicaltrials.gov/ct2/show/NCT04679389

May 20th, 2022 - This study is double-blind, placebo-controlled, 1:1 randomized clinical therapeutic trial of acetazolamide for the treatment of ataxia in patients with PMM2-CDG. Clinical history and screening data will be reviewed to determine subject eligibility. Potential subjects who have a molecularly and/or biochemical confirmed diagnosis of PMM2-CDG will be consented. Baseline data will be collected prio...